How to Get Rezdiffra (Resmetirom) in New York

The direct answer

Rezdiffra (resmetirom) is available in New York through any licensed prescriber, in person or via telehealth, once a patient has a confirmed MASH diagnosis with fibrosis stage F2 or F3 documented by biopsy or a validated noninvasive method, and once the prescriber's office completes insurer prior authorization. The FDA approved resmetirom under accelerated approval in March 2024 based on a surrogate histologic endpoint in the MAESTRO-NASH trial, not on confirmed clinical outcomes such as reduced cirrhosis or mortality, so ongoing outcome data collection is part of the approval condition. For New York patients specifically, state licensure law permits telehealth prescribing of resmetirom because it is not a controlled substance, but insurer-specific prior authorization requirements, exact processing times, and current cash price are all date-sensitive facts that must be confirmed with the plan, pharmacy, or manufacturer at the time of the visit rather than assumed from any general guide.

What Rezdiffra is, and what the approval does and does not establish

Resmetirom is a small-molecule, liver-directed thyroid hormone receptor beta (THR-β) agonist. It is designed to act selectively on the liver rather than systemically, which is the pharmacologic rationale for why it does not appear to produce the bone loss and cardiac stimulation seen with older, non-selective thyroid hormone agonists.

The FDA indication is specific: adults with MASH and moderate-to-advanced fibrosis (stages F2 and F3), taken with diet and exercise. It is not indicated for earlier fibrosis (F0-F1) or for compensated or decompensated cirrhosis (F4), and it is contraindicated in decompensated cirrhosis. Because the approval was granted on an accelerated basis using a histologic surrogate endpoint (MASH resolution and fibrosis improvement on biopsy), confirmed clinical benefit on outcomes like progression to cirrhosis, liver transplant, or death has not yet been established and is being evaluated in a longer-term outcomes trial. Patients should understand this distinction: the trial evidence supports a biopsy-measured improvement at 52 weeks, not yet a proven reduction in liver-related death or transplant.

In the phase 3 MAESTRO-NASH trial (N=966), resmetirom 80 mg achieved MASH resolution without worsening fibrosis in a meaningfully higher proportion of patients than placebo at 52 weeks, and a similar pattern held for fibrosis improvement of at least one stage. The most common adverse effects reported were diarrhea and nausea, generally mild to moderate. Readers who want exact percentages should consult the primary trial report directly, since secondary summaries (including earlier versions of this page) have sometimes overstated precision. See Harrison et al., N Engl J Med 2024, indexed at pubmed.ncbi.nlm.nih.gov/38324483.

A 2026 pharmacotherapy review covering FDA-approved and emerging MASH agents situates resmetirom as the first approved drug in a still-developing treatment class, useful context for understanding why step therapy is uncommon (there is no older approved comparator) but why insurers still often require documented lifestyle intervention first. See pubmed.ncbi.nlm.nih.gov/42564069.

Who is, and is not, a candidate

Rezdiffra is intended for adults with a confirmed diagnosis of MASH and fibrosis stage F2 or F3. Confirmation is typically done by liver biopsy (the reference standard) or by a validated noninvasive method such as vibration-controlled transient elastography (FibroScan) or MRI-based elastography, generally combined with elevated liver enzymes. The 2023 AASLD practice guidance on nonalcoholic fatty liver disease supports noninvasive staging as an accepted alternative to biopsy in appropriate patients, which is part of why insurers increasingly accept FibroScan-based staging for prior authorization, though this varies by plan. See pubmed.ncbi.nlm.nih.gov/36727674.

Rezdiffra is not appropriate for patients with decompensated cirrhosis (Child-Pugh B or C), and it is not FDA-indicated for fibrosis stages F0, F1, or F4. It should not be used in pregnancy; effects on fetal development have not been established. Resmetirom is metabolized primarily through CYP2C8, so strong CYP2C8 inhibitors (gemfibrozil is the labeled example) require caution or avoidance. This is general labeling information, not individualized dosing guidance; a prescriber must review a patient's full medication list and liver status before starting or adjusting therapy.

Getting evaluated and prescribed in New York

Any physician licensed in New York (MD or DO) can prescribe Rezdiffra. Nurse practitioners with prescriptive authority under New York law and physician assistants practicing under a collaborative or supervising arrangement can also prescribe, consistent with their state scope of practice. Hepatologists and gastroenterologists are the most experienced prescribers for MASH staging and monitoring, but primary care and endocrinology practices familiar with metabolic liver disease also initiate therapy in some cases. Exact scope-of-practice rules for NPs and PAs in New York can change; verify current requirements with the New York State Education Department if this affects a specific care plan.

Before prescribing, a provider typically orders a baseline panel: comprehensive metabolic panel (including ALT, AST, albumin, bilirubin), complete blood count, thyroid function tests (TSH and free T4, since THR-β agonism can suppress TSH), a lipid panel, and fibrosis staging (FIB-4 calculation plus biopsy or elastography). A pregnancy test is needed for patients who could become pregnant.

After starting treatment, monitoring generally includes periodic liver function testing and thyroid function testing, with the FDA label describing conditions (such as a marked ALT rise or signs of hepatic decompensation) under which the drug should be discontinued. The specific monitoring interval a given practice uses should come from the prescriber and the current FDA label, not from a generalized schedule, since labeling and clinical practice can be updated.

Telehealth in New York: what is settled and what still needs a phone call

New York permits telehealth evaluation and prescribing for non-controlled medications, and resmetirom is not a controlled substance, so telehealth access is not blocked by drug-scheduling rules. A telehealth visit for Rezdiffra typically involves a video consultation, review of previously obtained lab and imaging results, and electronic transmission of the prescription to a specialty pharmacy.

What telehealth does not solve on its own: the prescriber still needs an active New York medical license (or equivalent authority to prescribe into New York), and the patient still needs fibrosis staging completed somewhere, which usually requires an in-person elastography or biopsy appointment even if the follow-up visits are virtual. Patients in areas of New York with fewer liver specialists, including parts of upstate and Long Island, may find telehealth most useful for the ongoing management visits rather than for the initial fibrosis-staging step.

Verification checklist: stable facts vs. facts you must confirm before your visit

Certain information about resmetirom access is determined by federal standards or clinical evidence and remains stable over time, while other details are controlled by specific insurers, New York's Medicaid program, or individual pharmacies and may shift frequently. The most common source of patient disappointment regarding resmetirom costs or wait times stems from mixing up these two types of information. Before accepting any figures cited in this article or elsewhere as current, verify them with the relevant insurance provider or pharmacy.

Stable, federal or clinical-evidence facts (verify against FDA/primary literature, low volatility):

• Resmetirom's FDA-approved indication (MASH with F2/F3 fibrosis, used with diet and exercise), confirm at fda.gov or accessdata.fda.gov
• The approval was granted under the accelerated approval pathway based on a histologic surrogate endpoint, with confirmatory outcome data still pending
• Core trial findings from MAESTRO-NASH (design, population, general direction of effect), pubmed.ncbi.nlm.nih.gov/38324483
• Contraindication in decompensated cirrhosis and the CYP2C8 drug interaction caution
• That resmetirom is not a scheduled/controlled substance under federal law

Date-sensitive facts you must reconfirm before or at your visit (verify with the payer, pharmacy, or state agency directly, and note the date you checked):

• Whether your specific commercial plan or your New York Medicaid managed care plan currently covers Rezdiffra, and under what prior authorization criteria (call member services or check the current formulary)
• How long prior authorization is actually taking with your plan right now (ask the prescriber's office, which tracks live turnaround times)
• Whether your plan requires a documented trial of lifestyle intervention before approval, and for how long
• The current list price, any manufacturer copay program terms, and patient assistance program eligibility (confirm directly with Madrigal Pharmaceuticals or the specialty pharmacy, since program terms and price change over time)
• Which specialty pharmacy your plan requires you to use, and whether a New York-based option is available
• Current New York scope-of-practice rules for NP and PA prescribing if your prescriber is not an MD/DO
• Whether a specific 503A compounding pharmacy is currently licensed in New York and able to source pharmaceutical-grade resmetirom, if a compounded dose is being considered (most patients will use the commercially manufactured tablet, not a compounded product)

Coverage: what is reasonably well supported, and what needs confirmation

New York Medicaid and most major commercial insurers operating in New York generally require prior authorization for Rezdiffra, following criteria that track the FDA label: documented MASH with F2 or F3 fibrosis, appropriate baseline labs, and absence of decompensated cirrhosis. That structure is consistent with how new specialty drugs are typically managed, but the specific approval criteria, appeal rights, and processing timelines are set by each plan and by New York insurance regulation, and they can change. If a prior authorization is denied, New York law provides an appeals process, including expedited review for urgent situations; the exact statute, deadlines, and current DFS contact information should be confirmed directly with the New York State Department of Financial Services rather than relied upon from a secondhand summary.

Cost is a similar story. Rezdiffra has been publicly reported as a high-cost specialty drug with a list price in the tens of thousands of dollars per year at launch. Manufacturer copay assistance has been described for commercially insured patients, and a patient assistance program has been described for uninsured or underinsured patients, but eligibility rules, program caps, and current pricing should be confirmed directly with Madrigal Pharmaceuticals or the dispensing specialty pharmacy, since these numbers are not stable over time and are outside the scope of a general access guide.

Compounded resmetirom: a narrow and unusual situation

Rezdiffra is a brand-name product, and resmetirom is not currently available as an FDA-approved generic. 503A compounding pharmacies in New York operate under New York State Board of Pharmacy oversight and federal compounding law, and in principle could compound a patient-specific formulation if a licensed prescriber writes for one and the pharmacy can source pharmaceutical-grade active ingredient. In practice, the overwhelming majority of patients will receive the commercially manufactured 80 mg or 100 mg tablet through a specialty pharmacy, and compounded resmetirom is not a typical or expected part of standard care. Anyone considering a compounded version should confirm the pharmacy's current New York license and ask the prescriber why a compounded product, rather than the FDA-approved tablet, is being considered.

Transferring an existing prescription into New York

New York pharmacy regulation generally allows prescription transfers between licensed pharmacies, including specialty pharmacies, for a prescription written by a provider licensed in a U.S. state or territory. Practically, this means contacting the current specialty pharmacy and requesting a transfer to a New York-licensed one. Prior authorization is tied to the insurance plan, not the state, so a patient who keeps the same commercial insurer after moving typically keeps the existing authorization, while a patient switching plans, including moving onto New York Medicaid, will likely need a new prior authorization submitted. Starting this process a few weeks ahead of the next refill reduces the risk of a treatment gap, though the clinical consequences of a short interruption in resmetirom have not been formally studied and should not be assumed to be trivial or serious without asking the prescriber.

When this is not the right resource

This article is a general access guide, not a substitute for a clinical evaluation. It cannot tell an individual reader whether their liver fibrosis stage, comorbidities, or medication list make resmetirom appropriate, and it does not provide dosing guidance. Anyone with signs of decompensated liver disease, such as jaundice, confusion, abdominal swelling, or gastrointestinal bleeding, needs urgent medical evaluation rather than a prior-authorization conversation.

Evidence boundary

Established: resmetirom's FDA-approved indication for MASH with F2/F3 fibrosis, its mechanism as a liver-directed THR-β agonist, the general design and direction of the MAESTRO-NASH trial results, its non-controlled status, and the general availability of telehealth prescribing under New York law. Plausible but not established by cited evidence: the degree of risk from a short interruption in therapy, and the exact clinical significance of TSH suppression outside trial populations. Not established, and outside the scope of a general guide: any single insurer's current prior authorization criteria or timeline, the current cash price of Rezdiffra, current copay or patient assistance program terms, and whether any specific 503A pharmacy in New York is presently compounding resmetirom. These facts require direct, dated verification with the payer, manufacturer, or pharmacy involved.